Correlation Engine 2.0
Clear Search sequence regions

  • child (1)
  • chorea (1)
  • diagnosis (1)
  • female (1)
  • haloperidol (6)
  • humans (1)
  • levetiracetam (9)
  • patients (4)
  • sodium (1)
  • sydenham chorea (5)
  • valproic acid (2)
  • Sizes of these terms reflect their relevance to your search.

    To study the effect of levetiracetam in treating Sydenham chorea. We retrospectively collected the data of 140 patients diagnosed with Sydenham chorea in the pediatric neurology and pediatric cardiology outpatient clinics of Van Training and Research Hospital between January 2010 and December 2018. There were 140 patients, 102 (70%) of whom were girls, with mean age of onset 11.8 ± 2.7 years. Symptomatic treatment was initiated in all patients at the time of diagnosis; this medication was changed during follow up in 15 patients. The most frequently prescribed drugs were haloperidol and sodium (Na) valproate, and the most frequently discontinued one was haloperidol, due to side effects. The second-choice drug was most often levetiracetam. Clinical response often began within the first 2 weeks, with Na valproate (P = 0.002), within 4 weeks with carbamazepine (P = 0.037) but 1-6 months with haloperidol (P = 0.018) and levetiracetam (P = 0.008). Time to full remission was similar with Na valproate, carbamazepine, haloperidol, and levetiracetam (P = 0.276). Our study indicated that levetiracetam was as effective as the other commonly used drugs in the symptomatic treatment of Sydenham chorea. Levetiracetam might be an option in the treatment of Sydenham chorea because of its acceptable effect and safety profile. This observation needs further support with evidence obtained through controlled and blinded trials. © 2020 Japan Pediatric Society.


    Meltem Direk, Serdar Epcacan, Zerrin Epcacan, Didem Derici Yildirim, Cetin Okuyaz. Efficacy of levetiracetam in the treatment of Sydenham chorea. Pediatrics international : official journal of the Japan Pediatric Society. 2020 Nov;62(11):1264-1268

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32445412

    View Full Text